Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:RZLT NASDAQ:TVGN NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$20.84-1.1%$22.58$12.21▼$39.12$583.46M-0.19502,877 shs679,572 shsRZLTRezolute$7.70-6.1%$6.62$2.21▼$8.81$699.24M0.03998,705 shs4.75 million shsTVGNTevogen Bio$0.76-7.7%$0.97$0.26▼$3.09$149.18M-0.78482,903 shs1.44 million shsTYRATyra Biosciences$12.50-2.3%$11.42$6.42▼$29.60$666.21M1.1218,676 shs393,689 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%-10.94%+2.36%-10.06%-43.01%RZLTRezolute0.00%+0.13%+10.63%+87.35%+58.11%TVGNTevogen Bio0.00%-12.83%-16.14%-36.80%+75.31%TYRATyra Biosciences0.00%-0.16%+6.84%+35.43%-46.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$20.84-1.1%$22.58$12.21▼$39.12$583.46M-0.19502,877 shs679,572 shsRZLTRezolute$7.70-6.1%$6.62$2.21▼$8.81$699.24M0.03998,705 shs4.75 million shsTVGNTevogen Bio$0.76-7.7%$0.97$0.26▼$3.09$149.18M-0.78482,903 shs1.44 million shsTYRATyra Biosciences$12.50-2.3%$11.42$6.42▼$29.60$666.21M1.1218,676 shs393,689 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%-10.94%+2.36%-10.06%-43.01%RZLTRezolute0.00%+0.13%+10.63%+87.35%+58.11%TVGNTevogen Bio0.00%-12.83%-16.14%-36.80%+75.31%TYRATyra Biosciences0.00%-0.16%+6.84%+35.43%-46.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.13121.33% UpsideRZLTRezolute 3.14Buy$14.4087.01% UpsideTVGNTevogen Bio 3.00Buy$10.001,218.57% UpsideTYRATyra Biosciences 3.14Buy$31.86154.86% UpsideCurrent Analyst Ratings BreakdownLatest TVGN, RZLT, TYRA, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/18/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.009/18/2025RZLTRezoluteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/16/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$45.009/10/2025TYRATyra BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.009/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.009/2/2025TYRATyra BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$35.008/22/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $20.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M6.39N/AN/A$2.33 per share8.94RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($0.09) per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)RZLTRezolute-$68.46M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)TVGNTevogen Bio-$13.73M-$0.19N/A∞N/AN/AN/A-775.49%11/10/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.78N/AN/AN/AN/A-31.22%-29.49%11/6/2025 (Estimated)Latest TVGN, RZLT, TYRA, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/A8/19/2025N/ATVGNTevogen Bio-$0.05-$0.03+$0.02-$0.03N/AN/A8/14/2025Q2 2025TYRATyra Biosciences-$0.53-$0.47+$0.06-$0.47N/AN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22RZLTRezoluteN/A14.378.43TVGNTevogen BioN/A0.260.26TYRATyra BiosciencesN/A21.9421.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ARZLTRezolute82.97%TVGNTevogen BioN/ATYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%RZLTRezolute18.39%TVGNTevogen Bio73.24%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableRZLTRezolute4090.81 million74.11 millionOptionableTVGNTevogen Bio3196.71 million52.64 millionN/ATYRATyra Biosciences2053.30 million45.20 millionOptionableTVGN, RZLT, TYRA, and ANAB HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Receives $31.86 Average PT from AnalystsSeptember 17, 2025 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Upgraded by Wall Street Zen to "Hold" RatingSeptember 15, 2025 | marketbeat.comWall Street Zen Upgrades Tyra Biosciences (NASDAQ:TYRA) to HoldSeptember 14, 2025 | americanbankingnews.comTyra Biosciences, Inc. $TYRA Shares Acquired by Jacobs Levy Equity Management Inc.September 12, 2025 | marketbeat.comTyra Biosciences price target raised to $36 from $30 at OppenheimerSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Has $1.31 Million Stock Holdings in Tyra Biosciences, Inc. $TYRASeptember 9, 2025 | marketbeat.comNMIBC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market PotentialSeptember 8, 2025 | theglobeandmail.comNuveen LLC Acquires New Stake in Tyra Biosciences, Inc. $TYRASeptember 7, 2025 | marketbeat.comWe're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash WiselySeptember 6, 2025 | finance.yahoo.comTyra Biosciences, Inc. $TYRA Shares Sold by Ally Bridge Group NY LLCSeptember 5, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Purchased by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comRaymond James Initiates Coverage of Tyra Biosciences (TYRA) with Strong Buy RecommendationSeptember 4, 2025 | msn.comTyra Biosciences management to meet with OppenheimerSeptember 4, 2025 | msn.comTyra Biosciences initiated with a Strong Buy at Raymond JamesSeptember 3, 2025 | msn.comWalleye Capital LLC Has $1.31 Million Stake in Tyra Biosciences, Inc. $TYRASeptember 1, 2025 | marketbeat.comAlphaQuest LLC Raises Stock Holdings in Tyra Biosciences, Inc. $TYRAAugust 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC WainwrightAugust 24, 2025 | marketbeat.comTyra Biosciences initiates paediatric study for achondroplasia treatmentAugust 22, 2025 | finance.yahoo.comTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaAugust 21, 2025 | prnewswire.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025Rezolute Stock: FDA Fast Track Fuels 2025 BreakoutBy Thomas Hughes | September 17, 2025TVGN, RZLT, TYRA, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$20.84 -0.24 (-1.14%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$20.84 +0.00 (+0.02%) As of 09/19/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Rezolute NASDAQ:RZLT$7.70 -0.50 (-6.10%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$7.93 +0.23 (+2.97%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Tevogen Bio NASDAQ:TVGN$0.76 -0.06 (-7.68%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.78 +0.02 (+2.32%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Tyra Biosciences NASDAQ:TYRA$12.50 -0.29 (-2.27%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$12.75 +0.25 (+1.99%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
